胶质母细胞瘤患者的试验效应:入组临床试验对总生存期的影响
该回顾性队列纳入365例胶质母细胞瘤患者,其中89例入组临床试验、276例未入组;经逆概率评分匹配后,入组临床试验者总生存期显著更长(28.8个月 vs 22.2个月,P=0.005)。作者认为临床试验倾向纳入预后较好的患者,但校正该偏倚后,入组临床试验仍是生存期延长的独立预测因素,且与治疗臂无关。
要点
- 入组临床试验者基线平均KPS评分更高、手术切除比例更高、更可能接受替莫唑胺治疗。
- 逆概率评分匹配后,入组临床试验者总生存期28.8个月 vs 未入组者22.2个月,P=0.005。
核心结论
- 临床试验倾向纳入预后特征最好的患者,但校正该偏倚后,入组临床试验仍是生存期延长的独立预测因素,且与治疗臂无关。
研究设计与样本
- 经机构审查委员会(IRB)批准,通过CPT和ICD编码识别患者,采用电子病历回顾性复习收集数据,必要时从在线讣告获取死亡数据。
- 共纳入365例胶质母细胞瘤患者,其中89例入组临床试验,276例未入组。
- 采用逆概率评分匹配将两组转化为可比队列,使用Kaplan-Meier曲线和Wilcoxon秩和检验比较生存。
主要发现
- 入组临床试验者基线平均KPS评分显著更高、手术切除比例更高、更可能接受替莫唑胺治疗。
- 逆概率评分匹配后,入组临床试验者生存显著长于未入组者(28.8个月 vs 22.2个月,P=0.005)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether participation in a clinical trial was associated with improved survival in patients with glioblastoma (GBM). METHODS: Following IRB approval, patients were identified using CPT and ICD codes. Data was collected using retrospective review of electronic medical records. When necessary, death data was obtained from online obituaries. Inverse propensity score matching was utilized to transform the two cohorts to comparable sets. Survival was compared using Kaplan-Meyer curves and Wilcoxon Rank Sum Test. RESULTS: In this cohort of 365 patients, 89 were enrolled in a clinical trial and 276 were not. Patients enrolled in clinical trials had a significantly higher mean baseline KPS score, higher proportion of surgical resections, and were more likely to receive temozolomide treatment than patients not enrolled in a clinical trial. After inverse propensity score matching, patients enrolled in a clinical trial lived significantly longer than those not enrolled (28.8 vs 22.2 months, p = 0.005). A potential confounder of this study is that patients not in a clinical trial had significantly fewer visits with neuro-oncologists than patients enrolled in a clinical trial (7 ± 8 vs 12 ± 9, p < 0. 0001). CONCLUSIONS: Clinical trials enroll patients with the most favorable prognostic features. Even when correcting for this bias, clinical trial enrollment is an independent predictor of increased survival regardless of treatment arm.
引用
- Melnick KF, Miller P, Carmichael E, et al. The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival. J Neurooncol. 2022. PMID: 35840786. doi:10.1007/s11060-022-04083-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。